Recent News

  • The Weight of Evidence

    Antoni Chan, MD, PhD
    icons representing weight, pain, gut and history

    Every rheumatologist knows this patient. Her ASDAS is 3.4. Her CRP is normal, her MRI is quiet, and she is on her third biologic. The reflex is to reach for a fourth. Abstracts from ACR Convergence 2026 make a quietly radical case against this reflex.

    Read Article
Akhil Sood MD, MS Tweet
@AkhilSoodMD
Lots of B-cell talk in SLE. What about T cells? Abstract 0258 targets the Treg By repleting lupus mice with IL-2 nanoparticles + histone peptides → • ↑ Tregs expansion • protection against protineuria and GN in lupus mice • ↑ Tregs in vitro of pts with SLE #ACR26 @RheumNow
Audrey Gibson Tweet
@Gibson_RheumPAC
Moura et al. (RISE GLP-1 RA/PsA cohort): Every 5% weight decrease after GLP-1 initiation was linked with lower pain and patient global scores in RA/PsA.@rheumnow #ACR2026 Abstract#0867
Audrey Gibson Tweet
@Gibson_RheumPAC
Moura et al. (RISE GLP-1 RA/PsA cohort): RAPID3 can improve after weight loss. Pain and patient global changed more than function. @rheumnow #ACR2026 Abstract#0867
Audrey Gibson Tweet
@Gibson_RheumPAC
Moura et al. (RISE GLP-1 RA/PsA cohort): When a patient on a GLP-1 says their joints feel better, how do we interpret RAPID3? Data link weight reduction with lower RAPID3 in RA/PsA. @rheumnow #ACR2026 Abstract#0867
Jiha Lee Tweet
@JihaRheum
GLP-1 weight loss improve RA/PsA symptoms? RISE (16.8K pts): each 5% ↓ weight ↓0.30 RAPID3 (MCID 3.5) ↑ odds of RAPID3 MCID (aOR 1.14; 95% CI 1.07-1.21). ↓ pain, PtGA > function Weight loss: potentially modifiable factor to improve PROs in RA/PsA. A#0867 @RheumNow #ACR26
Licia Mota Tweet
@Mota_licia_reum
Are we overlooking weight management in RA and PsA? #ACR26 Abstract 0867: Each 5% weight loss after GLP-1 RA initiation was linked to 14% higher odds of meaningful RAPID3 improvement. Beyond DMARDs: weight management deserves attention. Association ≠ causation. @RheumNow https://t.co/LY8wCO7w4g
Mrinalini Dey Tweet
@DrMiniDey
It's time for the Plenary at #ACR26! First up, GLP1 data in IA: In 1880 RA/PsA patients with paired data, each 5% weight loss after semaglutide/tirzepatide was assoc with 14% higher odds of clinically meaningful RAPID3 improvement. #0867 @Rheumnow
Eric Dein Tweet
@ericdeinmd
#ACR26 @RheumNow Ab#0867 GLP-1 in RA/PsA McCormick, @RADoctor RISE pts initiating GLP-1 Rx, retrospective from 2018-2024. Bean BMI 35.4 at initiation, basleine RAPID3 13.8 Mean wt reduction 15.6 lb at 12mo, RAPID3 reduc 0.3 pt Each 5% decr in body wt assoc w aOR 1.14 https://t.co/kTrfEWmF0n
Adela Castro Tweet
@AdelaCastro222
PsA Carries the Cardiometabolic Load in SpA A retrospective study of 320 SpA patients (PsA (n=158), axSpA (n=85), IBD-RA (n=44), ReA (n=18) and uSpA (n=15)) stratified by phenotype: isolated axial (n=59), peripheral (n=148), or combined axial and peripheral (n=113) disease.

Video

Podcasts

  • 3 x IL-23 = IL do Better (11.6.2026)
  • Individualized PsA Treatment With an IL-23i or a JAKi
  • DERM on RheumNow PODCAST (October 2026)
  • Mixed Drinks, Mixed Results (10.30.2026)
Ask Cush Anything

Submit your Rheumatology question or case here

Therapeutic Updates

Individualized PsA Treatment With an IL-23i or a JAKi

Sponsored by AbbVie Medical Affairs + Health Impact
AbbVie November RX Update
In Part 2 of our PsA management series, Saakshi Khattri, MD, and Lindsay Tom, PA-C, discuss tailoring treatment for patients with multidomain PsA and how IL-23i and JAKi data guide their decisions
Read Post
×